Document text
Principal Investigator: Robert P. Kimberly
Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Fiscal Year: 2020
Award: $587,941
Funding agency: National Center for Advancing Translational Sciences
ABSTRACT
The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating impact on the health
of communities, clinically, socially and economically. Preventive approaches require an understanding of the
virus prevalence and herd immunity in the general population. To evaluate the sero-prevalence of immunity
against SARS-COV-2 in the United States, this scientific partnership of academic medical centers and the
NIH’s intramural research program will examine the population prevalences of detectable antibodies to SARS-
COV-2 from a convenience sampling of adults in the U.S. who have not been diagnosed with COVID-19 (Aim
1) and will determine the immune attributes associated with health outcomes (Aim 2), including for those in
underrepresented populations and across the life course. From a cohort of >400,000 self-referred,
asymptomatic adults nationwide, a near-representative subset will be selected based on demographics such
as age, race/ethnicity, and geography to provide blood samples for characterization of antibodies and other
immunologic markers to inform the development of screening and neutralization assays. This work benefits
from the deep expertise in the basic and applied research of infectious diseases as well as viral vaccine
development, host immune response to viruses, and viral molecular biology and genetics at the National
Institute for Allergy and Infectious Diseases (NIAID). It also leverages the rigorous and efficient capacity
maintained by Clinical and Translational Science Awards (CTSA) Hubs to rapidly engage diverse cohorts of
participants nationally to accelerate translational research that is high priority scientifically and for eventual
public health practice. From this study, the collaborative team will gain crucial insights into the magnitude of the
COVID-19 pandemic across the country and will identify potential targets for a vaccine. These data are
essential to assess the impact of public health efforts and to guide ongoing COVID-19 response.
Terms: <19S Gamma Globulin><2019 novel coronavirus><2019-nCoV><21+ years old><7S Gamma Globulin><Academic Medical Centers><Adult><Adult Human><Antibodies><Antibody titer measurement><Applied Research><Applied Science><Assay><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood Sample><Blood Serum><Blood specimen><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Clinical><Clinical Sciences><Clinical and Translational Science Awards><Community Health><Country><DNA Molecular Biology><Data><Development><Diagnosis><Disease><Disease Outbreaks><Disorder><ELISA><Economics><Enzyme-Linked Immunosorbent Assay><Epidemic><Ethnic Origin><Ethnicity><Future><General Population><General Public><Geography><Goals><Grippe><Health><Herd Immunity><Humoral Immunities><IgG><IgM><Immune><Immune Markers><Immune response><Immunes><Immunity><Immunoglobulin G><Immunoglobulin M><Immunologic Markers><Immunological response><Individual><Infection><Infectious Diseases / Laboratory><Infectious Diseases Research><Influenza><Intramural Program><Intramural Research Program><Knowledge><Life Cycle><Life Cycle Stages><MERS><MERS coronavirus disease><MERS-CoV disease><Measures><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Molecular Biology><Molecular Genetics><Morbidity><Morbidity - disease rate><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Natural History><Outbreaks><Outcome><Participant><Population><Prevalence><Preventive><Proteins><Public Health><Public Health Practice><Race><Racial Group><Racial Stocks><SARS><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Seroprevalences><Serum><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Special Population><Translational Research><Translational Science><Underrepresented Populations><United States><United States National Institutes of Health><University Medical Centers><Vaccines><Viral><Viral Vaccines><Virus><Work><Wuhan coronavirus><adulthood><antibody titering><antibody-based immunity><base><bio-markers><biologic marker><biomarker><clinical center><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><demographics><develop a vaccine><development of a vaccine><developmental><flu infection><host response><immune-based biomarkers><immunological biomarkers><immunological markers><immunoresponse><influenza infection><insight><life course><mortality><named group><novel><pandemic><pandemic disease><pathogen><respiratory virus><response><screening><social><translation research><vaccine development><vaccine formulation>